Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients

Andrés Jaramillo, Kishore Narayanan, Lacey G. Campbell, Nicholas D. Benshoff, Lonnie Lybarger, Ted H. Hansen, Timothy P. Fleming, Jill R. Dietz, T. Mohanakumar

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

A breast cancer-associated antigen, mammaglobin-A, is specifically expressed in 80% of primary breast tumors. The definition of immune responses against this highly expressed breast cancer-specific antigen should be of great value in the development of new therapeutic strategies for breast cancer. Thus, the purpose of this study was to identify HLA-A2-restricted mammaglobin-A- derived epitopes recognized by CD8+ cytotoxic T lymphocytes (CTL). We identified seven mammaglobin-A-derived candidate epitopes that bind the HLA-A2 molecule (Mam-A2.1-7) by means of a HLA class I-peptide binding computer algorithm from the Bioinformatics & Molecular Analysis Section of the National Institutes of Health. Subsequently, we determined that CD8+ CTLs from breast cancer patients reacted to the Mam-A2.1 (83-92, LIYDSSLCDL), Mam-A2.2 (2-10, KLLMVLMLA), Mam-A2.3 (4-12, LMVLMLAAL), Mam-A2.4 (66-74, FLNQTDETL), and Mam-A2.7 (32-40, TINPQVSKT) epitopes using an IFN-c ELISPOT assay. Interestingly, healthy individuals also showed high reactivity to the Mam-A2.2 epitope. Two CD8+ CTL lines generated in vitro against TAP-deficient T2 cells loaded with the candidate epitopes showed significant cytotoxic activity against the Mam-A2.1-4 epitopes. These CD8+CTL lines recognized a HLA-A2+breast cancer cell line expressing the Mam-A2.1 epitope. In addition, DNA vaccination of HLA-A2+/human CD8+ double-transgenic mice with a DNA construct encoding the Mam-A2.1 epitope and the HLA-A2 molecule induced a significant expansion of epitope-specific CD8+ CTLs that recognize the same HLA- A2+/Mam-A2.1+ breast cancer cell line. In conclusion, these results demonstrate the immunotherapeutic potential of mammaglobin-A for the treatment and prevention of breast cancer.

Original languageEnglish (US)
Pages (from-to)29-41
Number of pages13
JournalBreast Cancer Research and Treatment
Volume88
Issue number1
DOIs
StatePublished - Nov 2004
Externally publishedYes

Fingerprint

Mammaglobin A
HLA-A2 Antigen
Cytotoxic T-Lymphocytes
Epitopes
Breast Neoplasms
Enzyme-Linked Immunospot Assay
Antigens
Cell Line
DNA
National Institutes of Health (U.S.)
Computational Biology
Transgenic Mice

Keywords

  • CD8+ T lymphocytes
  • epitope
  • HLA-A2
  • mammaglobin-A
  • tumor-specific antigen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients. / Jaramillo, Andrés; Narayanan, Kishore; Campbell, Lacey G.; Benshoff, Nicholas D.; Lybarger, Lonnie; Hansen, Ted H.; Fleming, Timothy P.; Dietz, Jill R.; Mohanakumar, T.

In: Breast Cancer Research and Treatment, Vol. 88, No. 1, 11.2004, p. 29-41.

Research output: Contribution to journalArticle

Jaramillo, A, Narayanan, K, Campbell, LG, Benshoff, ND, Lybarger, L, Hansen, TH, Fleming, TP, Dietz, JR & Mohanakumar, T 2004, 'Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients', Breast Cancer Research and Treatment, vol. 88, no. 1, pp. 29-41. https://doi.org/10.1007/s10549-004-8918-1
Jaramillo, Andrés ; Narayanan, Kishore ; Campbell, Lacey G. ; Benshoff, Nicholas D. ; Lybarger, Lonnie ; Hansen, Ted H. ; Fleming, Timothy P. ; Dietz, Jill R. ; Mohanakumar, T. / Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients. In: Breast Cancer Research and Treatment. 2004 ; Vol. 88, No. 1. pp. 29-41.
@article{7fbc2c64a5ee4dc49ccd289fd405d036,
title = "Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients",
abstract = "A breast cancer-associated antigen, mammaglobin-A, is specifically expressed in 80{\%} of primary breast tumors. The definition of immune responses against this highly expressed breast cancer-specific antigen should be of great value in the development of new therapeutic strategies for breast cancer. Thus, the purpose of this study was to identify HLA-A2-restricted mammaglobin-A- derived epitopes recognized by CD8+ cytotoxic T lymphocytes (CTL). We identified seven mammaglobin-A-derived candidate epitopes that bind the HLA-A2 molecule (Mam-A2.1-7) by means of a HLA class I-peptide binding computer algorithm from the Bioinformatics & Molecular Analysis Section of the National Institutes of Health. Subsequently, we determined that CD8+ CTLs from breast cancer patients reacted to the Mam-A2.1 (83-92, LIYDSSLCDL), Mam-A2.2 (2-10, KLLMVLMLA), Mam-A2.3 (4-12, LMVLMLAAL), Mam-A2.4 (66-74, FLNQTDETL), and Mam-A2.7 (32-40, TINPQVSKT) epitopes using an IFN-c ELISPOT assay. Interestingly, healthy individuals also showed high reactivity to the Mam-A2.2 epitope. Two CD8+ CTL lines generated in vitro against TAP-deficient T2 cells loaded with the candidate epitopes showed significant cytotoxic activity against the Mam-A2.1-4 epitopes. These CD8+CTL lines recognized a HLA-A2+breast cancer cell line expressing the Mam-A2.1 epitope. In addition, DNA vaccination of HLA-A2+/human CD8+ double-transgenic mice with a DNA construct encoding the Mam-A2.1 epitope and the HLA-A2 molecule induced a significant expansion of epitope-specific CD8+ CTLs that recognize the same HLA- A2+/Mam-A2.1+ breast cancer cell line. In conclusion, these results demonstrate the immunotherapeutic potential of mammaglobin-A for the treatment and prevention of breast cancer.",
keywords = "CD8+ T lymphocytes, epitope, HLA-A2, mammaglobin-A, tumor-specific antigen",
author = "Andr{\'e}s Jaramillo and Kishore Narayanan and Campbell, {Lacey G.} and Benshoff, {Nicholas D.} and Lonnie Lybarger and Hansen, {Ted H.} and Fleming, {Timothy P.} and Dietz, {Jill R.} and T. Mohanakumar",
year = "2004",
month = "11",
doi = "10.1007/s10549-004-8918-1",
language = "English (US)",
volume = "88",
pages = "29--41",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients

AU - Jaramillo, Andrés

AU - Narayanan, Kishore

AU - Campbell, Lacey G.

AU - Benshoff, Nicholas D.

AU - Lybarger, Lonnie

AU - Hansen, Ted H.

AU - Fleming, Timothy P.

AU - Dietz, Jill R.

AU - Mohanakumar, T.

PY - 2004/11

Y1 - 2004/11

N2 - A breast cancer-associated antigen, mammaglobin-A, is specifically expressed in 80% of primary breast tumors. The definition of immune responses against this highly expressed breast cancer-specific antigen should be of great value in the development of new therapeutic strategies for breast cancer. Thus, the purpose of this study was to identify HLA-A2-restricted mammaglobin-A- derived epitopes recognized by CD8+ cytotoxic T lymphocytes (CTL). We identified seven mammaglobin-A-derived candidate epitopes that bind the HLA-A2 molecule (Mam-A2.1-7) by means of a HLA class I-peptide binding computer algorithm from the Bioinformatics & Molecular Analysis Section of the National Institutes of Health. Subsequently, we determined that CD8+ CTLs from breast cancer patients reacted to the Mam-A2.1 (83-92, LIYDSSLCDL), Mam-A2.2 (2-10, KLLMVLMLA), Mam-A2.3 (4-12, LMVLMLAAL), Mam-A2.4 (66-74, FLNQTDETL), and Mam-A2.7 (32-40, TINPQVSKT) epitopes using an IFN-c ELISPOT assay. Interestingly, healthy individuals also showed high reactivity to the Mam-A2.2 epitope. Two CD8+ CTL lines generated in vitro against TAP-deficient T2 cells loaded with the candidate epitopes showed significant cytotoxic activity against the Mam-A2.1-4 epitopes. These CD8+CTL lines recognized a HLA-A2+breast cancer cell line expressing the Mam-A2.1 epitope. In addition, DNA vaccination of HLA-A2+/human CD8+ double-transgenic mice with a DNA construct encoding the Mam-A2.1 epitope and the HLA-A2 molecule induced a significant expansion of epitope-specific CD8+ CTLs that recognize the same HLA- A2+/Mam-A2.1+ breast cancer cell line. In conclusion, these results demonstrate the immunotherapeutic potential of mammaglobin-A for the treatment and prevention of breast cancer.

AB - A breast cancer-associated antigen, mammaglobin-A, is specifically expressed in 80% of primary breast tumors. The definition of immune responses against this highly expressed breast cancer-specific antigen should be of great value in the development of new therapeutic strategies for breast cancer. Thus, the purpose of this study was to identify HLA-A2-restricted mammaglobin-A- derived epitopes recognized by CD8+ cytotoxic T lymphocytes (CTL). We identified seven mammaglobin-A-derived candidate epitopes that bind the HLA-A2 molecule (Mam-A2.1-7) by means of a HLA class I-peptide binding computer algorithm from the Bioinformatics & Molecular Analysis Section of the National Institutes of Health. Subsequently, we determined that CD8+ CTLs from breast cancer patients reacted to the Mam-A2.1 (83-92, LIYDSSLCDL), Mam-A2.2 (2-10, KLLMVLMLA), Mam-A2.3 (4-12, LMVLMLAAL), Mam-A2.4 (66-74, FLNQTDETL), and Mam-A2.7 (32-40, TINPQVSKT) epitopes using an IFN-c ELISPOT assay. Interestingly, healthy individuals also showed high reactivity to the Mam-A2.2 epitope. Two CD8+ CTL lines generated in vitro against TAP-deficient T2 cells loaded with the candidate epitopes showed significant cytotoxic activity against the Mam-A2.1-4 epitopes. These CD8+CTL lines recognized a HLA-A2+breast cancer cell line expressing the Mam-A2.1 epitope. In addition, DNA vaccination of HLA-A2+/human CD8+ double-transgenic mice with a DNA construct encoding the Mam-A2.1 epitope and the HLA-A2 molecule induced a significant expansion of epitope-specific CD8+ CTLs that recognize the same HLA- A2+/Mam-A2.1+ breast cancer cell line. In conclusion, these results demonstrate the immunotherapeutic potential of mammaglobin-A for the treatment and prevention of breast cancer.

KW - CD8+ T lymphocytes

KW - epitope

KW - HLA-A2

KW - mammaglobin-A

KW - tumor-specific antigen

UR - http://www.scopus.com/inward/record.url?scp=8744288783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8744288783&partnerID=8YFLogxK

U2 - 10.1007/s10549-004-8918-1

DO - 10.1007/s10549-004-8918-1

M3 - Article

C2 - 15538043

AN - SCOPUS:8744288783

VL - 88

SP - 29

EP - 41

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -